Brad Haverkos, MD
Associate Professor, Medicine-Hematology

Photo
Download CV
Medical School:
  • MD, Wright State University Boonshoft School of Medicine (2009)
Graduate Schools :
  • MPH, Wright State University (2009)
  • MS, Ohio State University, The (2015)
Undergraduate School:
  • BA, Miami University of Ohio (OH) (2003)
Residency:
  • University of Illinois College of Medicine at Chicago Program, Internal Medicine (2012)
Fellowships:
  • Ohio State University Hospital Program, Hematology and Oncology (2015)
Languages: English
Department: Medicine-Hematology

Research Interests

Dr. Haverkos’ research focuses on developing novel management and treatment strategies in aggressive lymphoma subtypes with a focus on mature T and NK cell lymphoproliferative disorders (LPDs), including T-cell lymphomas. He collaborates with multiple laboratories with the goal of improving our understanding on the etiopathogenesis of T and NK/T-cell LPDs. He aims to translate discoveries grounded in this translational research into early phase clinical trials, which will lead to better patient outcomes. Recently, his research efforts center on identifying markers that prognosticate and predict response to specific therapies. He is also interested in improving clinical practice guidelines for patients with blood cancers.

Publications

  • Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1460-1467. PubMed PMID: 33152703
  • Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020 Sep 8;4(17):4256-4266. PubMed PMID: 32898250
  • Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K d/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel). 2020 Aug 15;12(8). PubMed PMID: 32824175
  • Evens AM, Danilov AV, Jagadeesh D, Sperling AL, Kim SH, Vaca RA, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond D, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Sarraf Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach CS, Straker-Edwards A, Klein A, Blum K, Boughan K, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre V, Zayac AS, Ramdial J, Maliske S, Epperla N, Venugopal P, Feldman T, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning M, Caimi PF, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. Blood. 2020 Jul 14. [Epub ahead of print] PubMed PMID: 32663292
  • Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncol. 2020 Jul 1;6(7):1011-1018. PubMed PMID: 32496525
  • Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 May 26;4(10):2227-2235. PubMed PMID: 32442301
  • Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020 May;18(5):522-536. PubMed PMID: 32380458
  • Haverkos BM, Porcu P. Improved outcomes for extranodal natural killer T-cell lymphoma. Lancet Haematol. 2020 Apr;7(4):e272-e273. PubMed PMID: 32105607
  • Hwang S, Johnson A, Fabbro S, Hastings J, Haverkos B, Chung C, Porcu P, William B. Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas: a single-institution experience. Br J Dermatol. 2020 Aug;183(2):386-387. PubMed PMID: 32078154
  • Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 May 15;126(10):2279-2287. PubMed PMID: 32049359
  • Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, Purev E, Haverkos BM, Tobin J, Kaiser J, Chase S, Miller M, Weinberg A, Gutman JA. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020 Apr;55(4):780-786. PubMed PMID: 31664185
  • Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, Purev E, Haverkos BM, Tobin J, Kaiser J, Chase S, Miller M, Weinberg A, Gutman JA. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2019 Oct 29. [Epub ahead of print] PubMed PMID: 31664185
  • Haverkos B. Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A hematologist's perspective. Clin Adv Hematol Oncol. 2019 Feb;17 Suppl 3(2):18-20. PubMed PMID: 31545305
  • Sokol K, Kartan S, Johnson WT, Alpdogan O, Nikbakht N, Haverkos BM, Gong J, Porcu P. Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). Front Oncol. 2019;9:509. PubMed PMID: 31263679
  • Dugan JP, Coleman CB, Haverkos B. Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders. Front Oncol. 2019;9:127. PubMed PMID: 30931253
  • Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan 10;12(1):6. PubMed PMID: 30630534
  • Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcu P. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). Cancer Treat Res. 2019;176:83-98. PubMed PMID: 30596214
  • Coleman CB, Lang J, Sweet LA, Smith NA, Freed BM, Pan Z, Haverkos B, Pelanda R, Rochford R. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol. 2018 Nov 1;92(21). PubMed PMID: 30089703
  • Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018 Jul 5;132(1):9-16. PubMed PMID: 29720488
  • Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr 24;2(8):933-940. PubMed PMID: 29685953
  • Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 Aug;24(8):1671-1677. PubMed PMID: 29684565
  • Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. Clin Cancer Res. 2018 Jul 15;24(14):3273-3281. PubMed PMID: 29632007
  • Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw. 2018 Feb;16(2):123-135. PubMed PMID: 29439173
  • Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med. 2017 Jul 6;377(1):89-91. PubMed PMID: 28679093
  • Haverkos BM, Coleman C, Gru AA, Pan Z, Brammer J, Rochford R, Mishra A, Oakes CC, Baiocchi RA, Freud AG, Porcu P. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discov Med. 2017 Mar;23(126):189-199. PubMed PMID: 28472613
  • Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 Jul 13;130(2):221-228. PubMed PMID: 28468799
  • Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2017 Apr;52(4):561-566. PubMed PMID: 28067870
  • Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. Expert Rev Hematol. 2017 Feb;10(2):111-121. PubMed PMID: 27998183
  • Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer. 2017 Apr 15;140(8):1899-1906. PubMed PMID: 27943278
  • Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. Expert Rev Hematol. 2016 Dec 26;:1-11. [Epub ahead of print] PubMed PMID: 27998183
  • Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas (PTCL). Int J Cancer. 2016 Dec 10. [Epub ahead of print] PubMed PMID: 27943278
  • Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Curr Hematol Malig Rep. 2016 Dec;11(6):514-527. PubMed PMID: 27778143
  • Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S181-S190.e4. PubMed PMID: 27521316
  • Yuan S, Yu J, Haverkos B, Su H. Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. Leuk Lymphoma. 2016 May;57(5):1194-6. PubMed PMID: 26734914
  • Gru AA, Haverkos BH, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, Vigil CE, Rochford R, Natkunam Y, Baiocchi RA, Porcu P. The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. Curr Hematol Malig Rep. 2015 Dec;10(4):456-67. PubMed PMID: 26449716
  • Haverkos B, Tyler K, Gru AA, Winardi FK, Frederickson J, Hastings J, Elkins C, Zhang X, Xu-Welliver M, Wong HK, Porcu P. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. Oncologist. 2015 Oct;20(10):1161-6. PubMed PMID: 26306900
  • Tyler KH, Haverkos BM, Hastings J, Hu E, Philips R, Gru AA, Welliver MX, Mishra A, Wong HK, Porcu P. The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. Front Oncol. 2015;5:136. PubMed PMID: 26137450
  • Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru AA. Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder. Am J Dermatopathol. 2015 Aug;37(8):604-13. PubMed PMID: 25839892
  • Sborov DW, Haverkos BM, Harris PJ. Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opin Investig Drugs. 2015 Jan;24(1):79-94. PubMed PMID: 25224845
View All (39 Total) View Less

Practice Locations

UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
1665 Aurora Court
3rd floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-6400

UCH - Anschutz Inpatient Pavilion
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

UCH - Dermatology Clinic
1665 Aurora Ct
3rd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0500

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Hematology and Oncology, Board Certification (2012)
  • Internal Medicine, Board Certification
  • Wyoming Physician, License (2020)
  • Nebraska Physician, License (2020)
  • New Mexico Physician, License (2020)
  • Colorado Physician, License (2015)
Conditions & Treatments
  • Cancers - Blood and Marrow Transplant
  • Cancers - Lymphoma
  • Cancers
Clinical Interests
My clinical interests include the treatment and management of lymphoma patients with a specific interest in T-cell lymphomas.

Personal Interests
Dr. Haverkos completed his bachelor’s degree at Miami University in Ohio. This was followed by receipt of a combined MD/MPH degree at Wright State University in Dayton, Ohio as part of the Boonshoft School of Medicine Physician Leadership Development Program. He moved to the University of Illinois in Chicago for his residency in Internal Medicine. He then completed his fellowship training in Hematology and Oncology at Ohio State University, where he also completed a Master’s degree in Medical Science and a NIH sponsored post-doctoral fellowship with an emphasis on immunology, virology, biostatistics, and clinical trial design. In 2015 he joined the lymphoma and BMT program at the University of Colorado. Dr. Haverkos is a principle investigator of multiple early-phase clinical trials. He has published and presented his research at the national and international level. He also serves as a reviewer for a number of medical journals and is a member on multiple professional organizations.

General Information

Medical Schools:
  • MD, Wright State University Boonshoft School of Medicine (2009)
Graduate Schools:
  • MPH, Wright State University (2009)
  • MS, Ohio State University, The (2015)
Undergraduate Schools:
  • BA, Miami University of Ohio (OH) (2003)
Residency Programs:
  • University of Illinois College of Medicine at Chicago Program, Internal Medicine (2012)
Fellowships:
  • Ohio State University Hospital Program, Hematology and Oncology (2015)
Download CV
Languages: English
Department: Medicine-Hematology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;